Quick Answer
Nuvation Bio Inc. reported R&D Expense of $115.11 million for fiscal year 2025.
Nuvation Bio Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $115.11M | +16.1% |
| 2024 | $99.12M | +39.0% |
| 2023 | $71.29M | -18.8% |
| 2022 | $87.81M | +27.2% |
| 2021 | $69.04M | +111.8% |
| 2020 | $32.60M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.85M | +4.0% | +5.4% |
| June 30, 2025 | $27.36M | -6.4% | +11.2% |
| March 31, 2025 | $24.60M | +91.6% | -11.3% |
| September 30, 2024 | $27.73M | +49.4% | -5.2% |
| June 30, 2024 | $29.25M | +57.3% | +127.7% |
| March 31, 2024 | $12.84M | -31.6% | -30.8% |
| September 30, 2023 | $18.56M | -12.8% | -0.2% |
| June 30, 2023 | $18.59M | -35.7% | -1.0% |
- Nuvation Bio Inc. showed an increase of +16.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Nuvation Bio Inc.’s r&d expense has grown by 253.1% (from $32.60 million to $115.11 million).
- The most recent figure is from Nuvation Bio Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: